247 related articles for article (PubMed ID: 9630503)
1. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
Kawasaki-Yatsugi S; Yatsugi S; Takahashi M; Toya T; Ichiki C; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
Brain Res; 1998 May; 793(1-2):39-46. PubMed ID: 9630503
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model.
Kawasaki-Yatsugi S; Ichiki C; Yatsugi S; Takahashi M; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
Neuropharmacology; 2000 Jan; 39(2):211-7. PubMed ID: 10670416
[TBL] [Abstract][Full Text] [Related]
3. YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
Takahashi M; Kohara A; Shishikura J; Kawasaki-Yatsugi S; Ni JW; Yatsugi S; Sakamoto S; Okada M; Shimizu-Sasamata M; Yamaguchi T
CNS Drug Rev; 2002; 8(4):337-52. PubMed ID: 12481190
[TBL] [Abstract][Full Text] [Related]
4. YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.
Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Yatsugi SI; Shimizu-Sasamata M; Koshiya K; Shishikura JI; Sakamoto S; Yamaguchi T
J Pharmacol Exp Ther; 1998 Feb; 284(2):467-73. PubMed ID: 9454786
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Ichiki C; Yatsugi SI; Koshiya K; Shimizu-Sasamata M; Yamaguchi T
J Pharmacol Exp Ther; 1998 Nov; 287(2):559-66. PubMed ID: 9808681
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.
Håberg A; Takahashi M; Yamaguchi T; Hjelstuen M; Haraldseth O
Brain Res; 1998 Nov; 811(1-2):63-70. PubMed ID: 9804894
[TBL] [Abstract][Full Text] [Related]
7. Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats.
Ni JW; Takahashi M; Yatsugi S; Shimizu-Sasamata M; Yamaguchi T
Neuroreport; 1998 Nov; 9(16):3719-24. PubMed ID: 9858385
[TBL] [Abstract][Full Text] [Related]
8. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.
Terai K; Suzuki M; Sasamata M; Yatsugi Si; Yamaguchi T; Miyata K
Eur J Pharmacol; 2003 Apr; 467(1-3):95-101. PubMed ID: 12706461
[TBL] [Abstract][Full Text] [Related]
9. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats.
Kawasaki-Yatsugi S; Ichiki C; Yatsugi S; Shimizu-Sasamata M; Yamaguchi T
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):586-91. PubMed ID: 9840429
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.
Hara H; Yamada N; Kodama M; Matsumoto Y; Wake Y; Kuroda S
Eur J Pharmacol; 2006 Feb; 531(1-3):59-65. PubMed ID: 16403498
[TBL] [Abstract][Full Text] [Related]
11. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist.
Kohara A; Okada M; Tsutsumi R; Ohno K; Takahashi M; Shimizu-Sasamata M; Shishikura J; Inami H; Sakamoto S; Yamaguchi T
J Pharm Pharmacol; 1998 Jul; 50(7):795-801. PubMed ID: 9720630
[TBL] [Abstract][Full Text] [Related]
12. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.
Shimizu-Sasamata M; Kano T; Rogowska J; Wolf GL; Moskowitz MA; Lo EH
Stroke; 1998 Oct; 29(10):2141-8. PubMed ID: 9756596
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia.
Umemura K; Shimakura A; Nakashima M
Brain Res; 1997 Oct; 773(1-2):61-5. PubMed ID: 9409705
[TBL] [Abstract][Full Text] [Related]
14. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
Kawasaki-Yatsugi S; Shimizu-Sasamata M; Yatsugi S; Yamaguchi T
J Pharm Pharmacol; 1998 Aug; 50(8):891-8. PubMed ID: 9751454
[TBL] [Abstract][Full Text] [Related]
15. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.
Yao H; Ibayashi S; Nakane H; Cai H; Uchimura H; Fujishima M
Brain Res; 1997 Apr; 753(1):80-5. PubMed ID: 9125434
[TBL] [Abstract][Full Text] [Related]
16. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats.
Nishiyama T; Gyermek L; Lee C; Kawasaki-Yatsugi S; Yamaguchi T
Anesth Analg; 1999 Jul; 89(1):143-7. PubMed ID: 10389792
[TBL] [Abstract][Full Text] [Related]
17. Administration of a competitive NMDA antagonist MDL-100,453 reduces infarct size after permanent middle cerebral artery occlusion in rat.
Jiang N; Zhang RL; Baron BM; Chopp M
J Neurol Sci; 1996 Jun; 138(1-2):36-41. PubMed ID: 8791236
[TBL] [Abstract][Full Text] [Related]
18. The systemically administered competitive AMPA receptor antagonist, YM872, has analgesic effects on thermal or formalin-induced pain in rats.
Nishiyama T; Gyermek L; Lee C; Kawasaki-Yatsugi S; Yamaguchi T
Anesth Analg; 1999 Dec; 89(6):1534-7. PubMed ID: 10589643
[TBL] [Abstract][Full Text] [Related]
19. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model.
Suzuki M; Sasamata M; Miyata K
Brain Res; 2003 Jan; 959(1):169-72. PubMed ID: 12480171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
